Business News

TABLET TECHNOLOGY

Nationwide soft launch of Sputnik V vaccine reaches 50 cities, towns in India:Dr Reddy’s Laboratories

Dr. Reddy’s has partnered with major hospitals across the country for this purpose, all of whom have successfully administered Sputnik V in India.

Sputnik V manufacturer in India Dr. Reddy’s Laboratories on Monday issued a statement saying the nationwide rollout of the Russian vaccine in India has now reached 50 cities and towns in India. “We will strengthen the commercial roll-out of Sputnik V in the coming weeks. Neither the ongoing soft commercial launch nor work towards its ramp-up

in India have been put on hold,” Dr. Reddy’s Laboratories said. In a statement on the Sputnik V vaccine in India, Dr. Reddy’s Laboratories said the Sputnik V vaccine was launched on a soft pilot basis in India on May 14 this year and its commercial roll-out will strengthen in the coming weeks.

“Dr. Reddy’s has partnered with major hospitals across the country for this purpose, all of whom have successfully administered Sputnik V in India, including ongoing commercial roll-outs to the public,” it added.


SRL Diagnostics allocates Rs 300-500 cr to expand lab, collection centres network

We are looking at both organic and inorganic routes for expansion. SRL has the strength of smoothly integrating large acquisitions.

SRL Diagnostics has allocated Rs 300-500 crore to expand its laboratory and collection centres network by the end of the next financial year, a top company official said. The leading diagnostics chain currently operates over 420

laboratories in 600 cities across 34 states and union territories. ”We have allocated Rs 300-500 crore for expansion needs up to FY23-end...he strategy for expanding the network lab will be determined by how much additional

Tcapacity is required in the cities SRL is currently present. Because of its large presence in over 600 cities, the current focus is to go deeper and wider in the markets that it is present in, he added.


Molbio Diagnostics’ Truenat testing platform gets emergency use approval for Nipah virus detection

Truenat RT-PCR platform is a decentralised molecular diagnostic tool that can test multiple diseases right at the first point of patient contact.

Goa-based Molbio Diagnostics has become the first Indian medical devices manufacturer to get Emergency Use Authorisation (EUA) from the Drug. Controller General of India (DCGI) for Truenat, an innovative point-of-care Real-Time PCR (RT-PCR) testing platform, to detect Nipah virus (NiV).

The approval comes in the wake of Nipah outbreak this week in Kerala’s Kozhikode. While one patient died because of the virus, nearly 280 are under isolation or observation. Prior to the current reported case from Kozhikode, India had reported three NiV outbreaks in the past

(Siliguri in 2001 and Nadia in 2007 (West Bengal) and Kozhikode and Malappuram in Kerala in 2018). NiV is an emerging zoonotic infection that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis.

FUTURE TABLET TECHNOLOGY

Six new innovations

Imprint focus on the evolution of tablets incorporating latest innovations. New trends like fast dissolving, lubrications, multilayered are driving investment into pharma machineries capex. State-of-the art tableting factory will need to boast of these new high-tech machines. Imprint will follow this article in subsequent issue researching which machines can produce new technology tablets



Among the different routes of drug administration, oral route is mostly preferred. About 90% of drugs are administered orally for systemic effect. Various kinds of solid dosage forms like tablet, capsules, pills, syrups etc are administered through oral route of drug administration. In orally administereddosage forms, tablet represents the preferred choice of class of product. The tablet is convenient, in terms of self medication, ease of administration, compactness, accurate dose, avoidance pain,versatility and most importantly patient compliance.



Excipient technology is
advancing to produce
directly
compressible
materials for both
immediate release as in mouth
dissolving systems,
or for sustained release
systems.



The recent trends in tablet formulation are

1.Versatile immediate release tablet systems including fast orally dispersible tablets, orally dispersible mini tablets, mouth dissolving / fast dissolving tablets, novel fixed dose combination tablet ACCU-BREAK technology inactive layer between two different drug layers), conventional effervescent, uncoated and film–coated tablets etc. 2. Modified release tablet formulations including ring cap coated tablet ALZA, layered tablets (in lay, tablet in tablet, bilayered tablet), novel chewable sustained release tablet and direct compression medicated chewing gum. 3. Excipient technology is advancing to produce directly compressible materials for both immediate release as in mouth dissolving systems, or for sustained release systems. The research in excipients is meeting pace with the high throughput production of tablets. Research is also advancing into obtaining excipients from natural sources. Various commercial excipients such as Lycoat, Readily coat, Instamodel and Instanute DR are available in the market.



37

38